UNSPSC 51263704: Adaprolol maleate

This classification denotes a beta-adrenergic blocking agent with the molecular formula C26H39NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2I8RV6WL9A, chemically known as benzeneacetic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, 2-tricyclo(3.3.1.1(sup 3,7))dec-1-ylethyl ester, (+-)-, (z)-2-butenedioate (1:1) (salt) but more generally known as adaprolol maleate, which bears US NIH Compound Identifier 6435805. Most nations, for tariff and trade purposes, schedule adaprolol maleate under HS 29221980 and SITC 51461.

As of Q4 2014, ADAPROLOL MALEATE remains US FDA's Preferred Term for this commodity. Adaprolol maleate bears US NLM identifiers UMLS ID C0645353 and NCI Concept Code C79960. SMILES: CC(C)NCC(COC1CCC(CC1)CC(=O)OCCC23CC4CC(C2)CC(C4)C3)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51263704 Adaprolol maleate is a Commodity code nominally designating a specific pharmaceutical ingredient, but recent state and local activity shows a marked mismatch between the code's narrow product scope and the work actually being solicited. The two recent opportunities tagged to this code involve naloxone procurement and pharmacy benefit program design — neither directly related to adaprolol maleate sourcing. State and local governments are using this code to tag pharmaceutical and drug-management acquisitions more broadly, including emergency response medications, drug deactivation systems, and pharmacy program strategy work. Issuing bodies have included county public health departments (Seminole County, Florida) and state health and human services agencies (Texas Health and Human Services Commission), with the latter conducting early-stage market research rather than executing a direct purchase.

Activity under this code is sparse and geographically limited to recent postings in Florida and Texas. Seminole County posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, seeking quarterly deliveries to its community health building in Sanford, Florida, with all shipping and delivery costs included in vendor proposals. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, framed as exploratory research to inform future procurement strategy rather than a binding solicitation. The code shows limited recent signal for traditional adaprolol maleate sourcing; vendors pursuing opportunities here should expect misalignment between the UNSPSC designation and the actual work being bought.